A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion

Trial Profile

A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Apixaban (Primary) ; Heparin; Warfarin
  • Indications Atrial fibrillation; Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMANATE
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Apr 2018 Primary endpoint (Number of Participants With All Cause Death) has not been met as per the results published in the European Heart Journal.
    • 06 Apr 2018 Primary endpoint (Number of Participants With Acute Stroke Event) has been met as per the results published in the European Heart Journal.
    • 06 Apr 2018 Results published in the European Heart Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top